
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BFI-751
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults
Details : BFI-751 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 13, 2021
Lead Product(s) : BFI-751
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
